Evidence map›Paper›PMID 39392159›Full record

ArticleJournal of the American Heart Association2024

Synthetic Antiangiogenic Vascular Endothelial Growth Factor-A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease.

Adarshini Raja, Vijay Ganta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Adarshini RajaMedical College of Georgia Augusta University Augusta GA USA.
Vijay GantaVascular Biology Center and Department of Medicine Augusta University Augusta GA USA.ORCID 0000-0002-2967-8320

Funding

A Two Amino Acid Switch in the Anti-angiogenic VEGF165b isoform creates a Novel Agent for Therapeutic Angiogenesis in Peripheral Artery DiseaseR01HL146673 · NHLBI · UNIVERSITY OF VIRGINIA · PI GANTA, VIJAY CHAITANYA · 2019 to 2023
$1.9M
NHLBI NIH HHS R01 HL146673
6 · The paper itself

Abstract

backgroundAlternative splicing in the eighth exon C-terminus of VEGF-A (vascular endothelial growth factor-A) results in the formation of proangiogenic VEGF METHODS AND

resultsHypoxia serum starvation was used as an in vitro peripheral artery disease model. Unilateral single ligation of the femoral artery was used as a preclinical peripheral artery disease model. VEGFR1 activating ligands have 2 arginine (RR) residues in their eighth exon C-terminus, that were replaced by lysine-aspartic acid (KD) in VEGF

conclusionsOur data shows that the KD residues regulate VEGF

Indexed as

Alternative SplicingDisease Models, AnimalIschemiaPeripheral Arterial DiseaseVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsAnimalsCell ProliferationHindlimbHumansMaleMiceMuscle, SkeletalNeovascularization, PhysiologicProtein IsoformsAngiogenesis InhibitorsKdr protein, mouseProtein IsoformsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2VEGFA protein, humanalternative splicinggrowth factorsischemiaphospho‐proteome arrayssignal transduction

Identifiers

PMID39392159
PMCPMC11935576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.